Status:
UNKNOWN
Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients
Lead Sponsor:
Hasselt University
Conditions:
Multiple Sclerosis
Paralytic Stroke
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Rationale: Approx. 80% of acute stroke patients suffer from acute hemiparesis. Stroke patients have not reached their full potential when they are discharged from hospital. It is proven that extra tra...
Detailed Description
All tests and exercises are pain free, easy to perform, non-intrusive, and not high demanding. Subjects will have to undergo an assessment via a movement protocol as well as clinical outcome tests. In...
Eligibility Criteria
Inclusion
- Clinically diagnosed with a central paresis of the arm/hand at entry in the study, caused by a supratentorial stroke;
- Post-stroke time more than 6 months (i.e. chronic phase after stroke);
- Having completed their active clinical rehabilitation program
- Hemiparesis featuring a low to moderate proximal (shoulder and arm) muscle strength:
- Motricity Index shoulder/arm item: minimum score of 14 and maximum 25 (out of 33), corresponding to a maximum active shoulder abduction of up to 90 degrees without resistance; and/or a minimum active shoulder anteflexion of 30 degrees and a maximum active range of motion of 120 degrees shoulder joint anteflexion which can actively be maintained for 10 seconds;
- a fair cognitive level, i.e. being able to understand the questionnaires and measurement instructions;
- ability to read and understand Dutch.
Exclusion
- Severe spasticity of the arm, i.e. Modified Ashworth Scale (MAS) score for the elbow and wrist flexors: each ≥ 3;
- Severe visual impairment and/or severe cognitive impairment which may interfere with the execution of the arm-hand tasks or the measurements;
- Severe neglect in the near extra personal space (38), established by the letter cancellation test (39) and Bell's test (quantitative evaluation, (40)) with a minimum omission score of 15% (Ferber, 2001);
- Broca aphasia, Wernicke aphasia, global aphasia: as determined by the Akense Afasie Test (AAT) (41);
- Severe apraxia as measured by the apraxia test of van Heugten (42);
- no informed consent.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01918748
Start Date
July 1 2013
End Date
September 1 2014
Last Update
August 8 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Revalidatie & MS Centrum Overpelt
Overpelt, Limburg, Belgium, 3900
2
Adelante Zorggroep
Hoensbroek, Netherlands, 6430 AB